Connect with us

Hi, what are you looking for?

News

Bristol Myers Squibb: Close To Fair Value, Headwinds For Next Few Years (NYSE:BMY)

When Bristol Myers Squibb (NYSE:BMY) acquired Celgene for $74 billion dollars in November of 2019, it was a combination of two struggling companies each trying to stay ahead of Merck in the oncology space. I remember

Read the full article here

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Videos

Watch full video on YouTube

News

This article was written by Follow Leo Nelissen is an analyst focusing on major economic developments related to supply chains, infrastructure, and commodities. He...